Pitavastatin - Lupin Pharmaceuticals

Drug Profile

Pitavastatin - Lupin Pharmaceuticals

Alternative Names: Nikita; Pitavastatin sodium

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lupin Pharmaceuticals
  • Class Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Hyperlipidaemia

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 09 Aug 2017 Lupin Pharmaceuticals has patent protection for pitavastatin sodium, worldwide
  • 09 Aug 2017 Registered for Hyperlipidaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top